GlassScriptPhysician profile
Cornelia Helene Pasquini
NPI 1932160579
$7,744.43
in general payments reported to CMS, 2019-2025
32 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,011 · 2022: $1,790 · 2023: $1,401 · 2024: $1,433 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,925 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,925.03 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,155.42 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Gallant |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $796.74 | 2021-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $710.89 | 2021-2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $629.01 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $500.79 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $458.37 | 2021-2025 | Farxiga, Lokelma, Wainua |
| Pfizer INC. | $387.36 | 2021-2025 | |
| Cvrx, INC. | $373.39 | 2022-2023 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $319.40 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $317.56 | 2021-2025 | |
| Amgen INC. | $229.96 | 2021-2024 | Repatha |
| Medtronic, INC. | $194.68 | 2021-2024 | Azure Xt Dr Mri Surescan, Reveal Linq |
| Esperion Therapeutics, INC. | $171.29 | 2021-2022 | |
| Scpharmaceuticals INC. | $153.61 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $153.52 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $150.00 | 2021 | |
| Abiomed | $141.73 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.87 | 2025 | |
| Bridgebio Pharma, INC. | $119.36 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $115.51 | 2022 | |
| Boston Scientific Corporation | $101.31 | 2022 | |
| Novo Nordisk INC | $98.79 | 2022-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.23 | 2021-2024 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $50.93 | 2023-2025 | Evkeeza, Praluent |
| Philips North America LLC | $50.20 | 2024 | (Cm9) Amb Mon & Diag Und |
| Sobi, INC | $45.80 | 2021 | |
| Inari Medical, INC. | $29.96 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $18.25 | 2024 | Arcalyst |
| Genzyme Corporation | $16.41 | 2021 | |
| Lilly USA, LLC | $16.21 | 2024 | Zepbound |
| Amarin Pharma, INC. | $14.94 | 2021 | |
| Chiesi USA, INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cornelia Pasquini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.